The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 22, 2025

Filed:

Aug. 09, 2019
Applicant:

Bioverativ Therapeutics Inc., Waltham, MA (US);

Inventors:

Tongyao Liu, Lexington, MA (US);

Alexey Seregin, Westford, MA (US);

Robert T. Peters, Needham, MA (US);

Jiayun Liu, Wellesley, MA (US);

Philip Zakas, Waltham, MA (US);

Douglas Drager, Waltham, MA (US);

Susannah Patarroyo-White, Waltham, MA (US);

Assignee:

BIOVERATIV THERAPEUTICS INC., Waltham, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/861 (2006.01); A61K 9/00 (2006.01); A61K 35/76 (2015.01); A61K 48/00 (2006.01); A61P 7/04 (2006.01); C07K 14/755 (2006.01); C12N 7/00 (2006.01); C12N 7/01 (2006.01); C12N 15/11 (2006.01); C12N 15/86 (2006.01);
U.S. Cl.
CPC ...
A61K 48/0058 (2013.01); A61K 9/0019 (2013.01); A61K 48/0016 (2013.01); A61K 48/0033 (2013.01); A61K 48/0066 (2013.01); A61P 7/04 (2018.01); C07K 14/755 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); C12N 2750/14143 (2013.01); C12N 2750/14171 (2013.01); C12N 2750/14343 (2013.01); C12N 2750/14371 (2013.01); C12N 2830/42 (2013.01); C12N 2830/50 (2013.01);
Abstract

The present disclosure provides nucleic acid molecules comprising a first inverted terminal repeat (ITR), a second ITR, and a genetic cassette encoding a target sequence. In some embodiments, the target sequence encodes a miRNA and/or a therapeutic protein. In certain embodiments, the therapeutic protein comprises a clotting factor, a growth factor, a hormone, a cytokine, an antibody, a fragment thereof, and a combination thereof. In some embodiments, the first ITR and/or the second ITR is an ITR of a non-adeno-associated virus (AAV). The present disclosure also provides methods of treating a metabolic disorder of the liver in a subject comprising administering to the subject the nucleic acid molecule or a polypeptide encoded thereby.


Find Patent Forward Citations

Loading…